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OBJECTIVE: To investigate the role of vitamin B  (nicotinamide) on midbrain dopaminergic
neuron development. BACKGROUND: The active forms of vitamins A & C are linked to
optimal development of neurons . Little is known regarding the role of vitamin B3 even
though poor cognitive development and parkinsonism were features of pellagra .
DESIGN/METHODS: Monolayer mouse embryonic stem cell cultures (mESC; Sox1GFP
knock-in 46C cell line) were treated with nicotinamide for different durations and
immunocytochemistry/ fluorescence microscopy was performed to assess the expression of
stem cell, neural progenitor (NP) and neuronal subtype markers. RESULTS: Nicotinamide
accelerated the conversion process of mESCs to neurons with a catecholaminergic phenotype.
Specifically, the proportion of proliferating cells was significantly reduced in nicotinamide-
treated cultures - that is, nicotinamide regulates the proliferation-to-differentiation switch
from NPs to neurons during development. Nicotinamide drives dopamine neuron
differentiation (10mM) as effectively as known cocktails of signalling factors, and acts in a
dose-dependent manner in a defined time-window - with high doses (20mM) however
causing toxicity. CONCLUSIONS: Nicotinamide aids the conversion of stem cells to
dopaminergic neurons increasing efficiency and safety of the cells produced, and reducing
cost; important as we progress towards patient-specific cell replacement therapy for
Parkinson’s . Our data also suggest that nicotinamide is a key signalling factor required in a
definable dosage range at key times for the formation of a healthy population of dopamine
neurons. An optimal maternal to foetal dietary dosage of nicotinamide - neither too low nor
too high - could be linked to Parkinson’s disease later in life.
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